Juan José Rodríguez-Sevilla

Aug 21, 2024 | digitalcommons.library.tmc.edu | Juan José Rodríguez-Sevilla |Irene Ganan-Gomez |Feiyang Ma |Kelly S. Chien

The molecular mechanisms of venetoclax-based therapy failure in patients with acute myeloid leukemia were recently clarified, but the mechanisms by which patients with myelodysplastic syndromes (MDS) acquire secondary resistance to venetoclax after an initial response remain to be elucidated.

Aug 21, 2024 | digitalcommons.library.tmc.edu | Juan José Rodríguez-Sevilla |Vera Adema |Guillermo Garcia-Manero |Simona Colla

Home > UTHealth > GSBS > Journal Articles > 518 Cell Reports Medicine myelodysplastic syndromes, hypomethylating agents, secondary acute myeloid leukemia, novel therapeutic agents DOWNLOADS Included in Bioinformatics Commons, Biological Phenomena, Cell Phenomena, and Immunity Commons, Biomedical Informatics Commons, Medical Cell Biology Commons, Oncology Commons COinS...

Feb 13, 2023 | cell.com | Juan José Rodríguez-Sevilla |Vera Adema |Guillermo Garcia-Manero |Simona Colla

Shastri A. Will B. Steidl U. Verma A. Stem and progenitor cell alterations in myelodysplastic syndromes. Blood. 2017; 129: 1586-1594https://doi.org/10.1182/blood-2016-10-696062Treatment of MDS. Blood. Blood. 2019; 133: 1096-1107Garcia-Manero G. Chien K.S. Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am. J. Hematol. 2020; 95: 1399-1420https://doi.org/10.1002/ajh.25950Fenaux P. Mufti G.J. Hellstrom-Lindberg E. Santini V. Finelli C. Giagounidis A.